Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents

Drugs of Today

Volumn 46, Issue 5, 2010, Pages 299-314

  Connor, Daniel F ^a   Rubin, J ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Shire Development Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; GUANFACINE; INTUNIV; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ADOLESCENT; APPETITE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CHILD; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERSOMNIA; HYPOTENSION; IMPULSIVENESS; IRRITABILITY; LETHARGY; NAUSEA; NEUROBIOLOGY; OPPOSITIONAL DEFIANT DISORDER; POSTTRAUMATIC STRESS DISORDER; PREFRONTAL CORTEX; PRESCHOOL CHILD; REVIEW; SCHOOL CHILD; SEDATION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TIC; UPPER ABDOMINAL PAIN; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; GUANFACINE; HUMANS;

EID: 77954750380     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.5.1450095     Document Type: Review

References (80)

1. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007, 46(7): 894-921.
2. American Psychiatric Association. Oppositional defiant disorder. In: Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Text Revision. Washington, DC: American Psychiatric Association 2000, 100-2.
3. Biederman, J., Faraone, S.V., Milberger, S. et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996, 35(9): 1193-204. (Pubitemid 26282600)
4. Pliszka, S.R., Carlson, CL., Swanson, J.M. Disruptive behavior disorders and substance abuse. In: ADHD With Comorbid Disorders: Clinical Assessment and Management. New York, NY: The Guilford Press; 1999: 89-112.
5. Biederman, J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005, 57(11): 1215-20.
6. Conners, C.K., Sitarenios, G., Parker, J.D.A., Epstein, J.N. The Revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998, 26(4): 257-68.
7. Biederman, J., Faraone, SV. Attention-deficit hyperactivity disorder. Lancet 2005, 366(9481): 237-48.
8. Brown, R.T., Freeman, W.S., Perrin, J.M. et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001, 107(3): E43.
9. Reiff, M.I., Stein, MT. Attention-deficit/hyperactivity disorder evaluation and diagnosis. A practical approach in office practice. Pediatr Clin North Am 2003, 50(5): 1019-48.
10. Olfson, M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care 2004, 10(4, Suppl.): S117-S124. (Pubitemid 38970247)
11. Pliszka, S.R., Crismon, M.L., Hughes, C.W. et al. and The Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/ Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45(6): 642-57.
12. Scahill, L., Barloon, L., Farkas, L. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychiatr Nurs 1999, 12(4): 168-73.
13. Scahill, L., Chappell, P.B., Kim, Y.S. et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001, 158(7): 1067-74.
14. Pliszka, S.R. Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 2003, 8(4): 253-8.
15. Waxmonsky, J.G. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol 2005, 6(5): 262-76.
16. Wilens, T.E., Faraone, S.V., Biederman, J., Gunawardene, S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003, 111(1): 179-85.
17. Molina, B.S.G., Flory, K., Hinshaw, S.P. et al. Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007, 46(8): 1027-39.
18. Faraone, S.V., Wilens, T.E. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry 2007, 68(Suppl. 11): 15-22.
19. Taylor, F.B., Russo, J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2001, 21(2): 223-8.
20. Hunt, R.D., Arnsten, A.F.T., Asbell, M.D. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995, 34(1): 50-4.
21. Chappell, P.B., Riddle, M.A., Scahill, L. et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995, 34(9): 1140-6.
22. Shojaei, A.H., Chang, R.-K., Pennick, M. Guanfacine extended release tablets as treatment for attention-deficit/hyperactivity disorder: Formulation characteristics. Poster presented at: U.S. Psychiatr Mental Health Congr (November 16-19, New Orleans) 2006, Poster presentation.
23. Boellner, S.W., Pennick, M., Fiske, K., Lyne, A., Shojaei, A. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007, 27(9): 1253-62.
24. Swearingen, D., Pennick, M., Shojaei, A., Lyne, A., Fiske, K. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007, 29(4): 617-25.
25. Intuniv [package insert]. Wayne, PA: Shire Pharmaceuticals Inc.; 2009.
26. Hunt, R.D., Minderaa, R.B., Cohen, D.J. Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985, 24(5): 617-29.
27. Connor, D.F., Fletcher, K.E., Swanson, J.M. A meta-analysis of Clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999, 38(12): 1551-9.
28. Hunt, R.D., Minderaa, R.B., Cohen, D.J. The therapeutic effect of Clonidine in attention deficit disorder with hyperactivity: A comparison with placebo and methylphenidate. Psychopharmacol Bull 1986, 22(1): 229-36.
29. Daviss, W.B., Patel, N.C., Robb, A.S. et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008, 47(2): 189-98.
30. Palumbo, D.R., Sallee, F.R., Pelham, W.E.Jr., Bukstein,O.G., Daviss, W.B., McDermott, M.P. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008, 47(2): 180-8.
31. Connor, D.F., Barkley, R.A., Davis, H.T. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000, 39(1): 15-25.
32. Hazell, P.L., Stuart, J.E. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003, 42(8): 886-94.
33. Schvehla, T.J., Mandoki, M.W., Sumner, G.S. Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: Preliminary findings in a children's inpatient unit. South Med J 1994, 87(7): 692-5.
34. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002, 58(4): 527-36.
35. Singer, H.S., Brown, J., Quaskey, S., Rosenberg, L.A., Mellits, E.D., Denckla, M.B. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95(1): 74-81.
36. Nair, V., Mahadevan, S. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. J Trop Pediatr 2009, 55(2): 116-21.
37. Jain, R., Kollins, S., Bailey, C., Holloway, W., Horacek, H.J., Khayrallah, M. Developing a sustained release formulation of Clonidine for the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD). 47th Annu Meet Am Coll Neuropsychopharmacol (December 7-11, Scottsdale) 2008.
38. Kollins, S., Findling, R.L., Wigal, S.B., Brams, M., Segal, S.D., Khayrallah, M. Modified release clonidine for the treatment of children and adolescents with ADHD. 56th Ann Meet Am Acad Child Adolescent Psychiatr (Oct 27-Nov 1, Honolulu) 2009, Poster presentation.
39. 2-noradrenergic mechanisms to prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996, 53(5): 448-55
40. Arnsten, A.F., Scahill, L., Findling, R.L. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Emerging concepts from new data. J Child Adolesc Psychopharmacol 2007, 17(4): 393-406.
41. Arnsten, A.F. Toward a new understanding of attentiondeficit hyperactivity disorder pathophysiology: An important role for prefrontal cortex dysfunction. CNS Drugs 2009, 23(Suppl. 1)33-41.
42. Arnsten, A.F. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009, 10(6): 410-22.
43. Shulman, G.L., Astafiev, S.V., Franke, D., Pope, D.L., Snyder, A.Z., McAvoy, M.P., Corbetta, M. Interaction of stimulus-driven reorienting and expectation in ventral and dorsal frontoparietal and basal ganglia-conical networks. J Neurosci 2009, 29(14): 4392-407.
44. Shomstein, S., Yantis, S. Control of attention shifts between vision and audition in human cortex. J Neurosci 2004, 24(47): 10702-6.
45. Casey, B.J., Epstein, J.N., Buhle, J. et al. Frontostriatal connectivity and its role in cognitive control in parent-child dyads with ADHD. Am J Psychiatry 2007, 164(11): 1729-36.
46. 2 adrenergic agonists. Neurochemistry, efficacy, and clinical guidelines for use in children. Pediatr Clin North Am 1998, 45(5): 1099-122.
47. 2A-selective compound. Eur J Pharmacol 1991, 202(2): 235-43.
48. 3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol 1994, 252(1): 43-9. (Pubitemid 2039079)
49. Arnsten, A.F.T., Cai, J.X., Goldman-Rakic, P.S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: Evidence for alpha-2 receptor subtypes. J Neurosci 1988, 8(11): 4287-98.
50. Wang, M., Ramos, B.P., Paspalas, C.D. et al. a2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007, 129(2): 397-410.
51. Southwick, S.M., Morgan, C.A., III, Charney, D.S., High, J.R. Yohimbine use in a natural setting: effects on posttraumatic stress disorder. Biol Psychiatry 1999, 46(3): 442-4.
52. Yeragani, V.K., Tancer, M., Uhde, T. Heart rate and QT interval variability: Abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res 2003, 121 (2): 185-96.
53. Biederman, J., Melmed, R.D., Patel, A., McBurnett, R., Konow, J., Lyne, A., Scherer, N.; SPD503 Study Group. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008, 121(1): e73-84.
54. Sallee, F., McGough, J., Wigal, T., Donahue, J., Lyne, A., Biederman J.; SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009, 48(2): 155-65.
55. Spencer, T.J., Greenbaum, M., Ginsberg, L.D., Murphy, W.R. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2009, 19(5): 501-10
56. Sallee, F.R., Lyne, A., Wigal, T., McGough, J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008, 19(3): 215-26.
57. Biederman, J., Melmed, R.D., Patel, A., McBurnett, K., Donahue, J., Lyne, A. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008, 13(12): 1047-55.
58. Barkley, R.A. Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychol Bull 1997, 121(1): 65-94.
59. Willcutt, E.G., Doyle, A.E., Nigg, J.T., Faraone, S.V., Pennington, B.F. Validity of the executive function theory of attention-deficit/hyperactivity disorder: A meta-analytic review. Biol Psychiatry 2005, 57(11): 1336-46.
60. Roth, R.M., Saykin, A.J. Executive dysfunction in attention-deficit/ hyperactivity disorder: Cognitive and neuroimoging findings. Psychiatr Clin North Am 2004, 27(1): 83-96. (Pubitemid 38367772)
61. Philipsen, A. Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. Eur Arch Psychiatry Clin Neurosci 2006, 256(Suppl. 1): 142-46.
62. Kollins, S.H., Spencer, T., Findling, R. et al. Effects of guanfacine extended release in children aged 6 to 12 with oppositional symptoms and a diagnosis of attention-deficit/hyperactivity disorder. 56th Annu Meet Am Acad Child Adolescent Psychiatr (Oct 27-Nov 1, Honolulu) 2009, Poster presentation.
63. Connor, D.F., Findling, R.L., Kollins, S.H., Sallee, F., Lopez, F.A., Lyne, A., Tremblay, G. Effects of guanfacine extended release, a nonstimulant alpha2a-adrenoceptor agonist, on oppositional symptoms in children aged 6 to 12 years with a diagnosis of attention-deficit/hyperactivity disorder CNS Drugs (in press).
64. Kisicki, J.C., Fiske, K., Lyne, A. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther 2007, 29(9): 1967-79.
65. Nami, R., Bianchini, C., Fiorella, G., Chierichetti, S.M., Gennari, C. Comparison of effects of guanfacine and clonidine on blood pressure, heart rate, urinary catecholamines, and cyclic nucleotides during and after administration to patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1983, 5(4): 546-51. (Pubitemid 13070986)
66. McElroy, S.L., Hudson, J.I., Pope, H.G. Jr., Keck, RE. Jr., Aizley, H.G. The DSM-III-R impulse control disorders not elsewhere classified: clinical characteristics and relationship to other psychiatric disorders. Am J Psychiatry 1992, 149 (3): 318-27.
67. McElroy, S.L., Soutullo, C.A., Beckman, D.A., Taylor, P. Jr., Keck, PE. Jr. DSM-IV intermittent explosive disorder: a report of 27 cases. J Clin Psychiatry 1998, 59(4): 203-10.
68. Hudson, J.I., Pope, H.G. Jr. Affective spectrum disorder: Does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry 1990, 147(5): 552-64.
69. Hudson, J.I., Mangweth, B., Pope, H.G. Jr. et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003, 60(2): 170-7.
70. Horrigan, J.P. Guanfacine for PTSD nightmares. J Am Acad Child Adolesc Psychiatry 1996, 35(8): 975-6.
71. Horrigan, J.P., Barnhill, L.J. The suppression of nightmares with guanfacine. J Clin Psychiatry 1996, 57(8): 371.
72. Neylan, T.C., Lenoci, M., Samuelson, K.W. et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006, 163(12): 2186-8.
73. Davis, L.L., Ward, C., Rasmusson, A., Newell, J.M., Frazier, E., Southwick, S.M. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008, 41(1): 8-18.
74. Riddle, M.A., Bernstein, G.A., Cook, E.H., Leonard, H.L., March, J.S., Swanson, J.M. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999, 38(5): 546-56.
75. Qasaymeh, M.M., Mink, J.W. New treatments for tic disorders. Curr Treat Options Neurol 2006, 8(6): 465-73.
76. Jimenéz-Jimenéz, F.J., García-Ruiz, P.J. Pharmacological options for the treatment of Tourette's disorder. Drugs 2001, 61(15): 2207-20.
77. Kossoff, E.H., Singer, H.S. Tourette syndrome: Clinical characteristics and current management strategies. Paediatr Drugs 2001, 3(5): 355-63.
78. Scahill, L., Chappell, P.B., King, R.A., Leckman, J.F. Pharmacologic treatment of tic disorders. Child Adolesc Psychiatr Clin N Am 2000, 9(1): 99-117.
79. Posey, D.J., Puntney, J.I, Sasher, T.M., Kem, D.L., McDougle, C.J. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004, 14(2): 233-41.
80. Cummings, D.D., Singer, H.S., Krieger, M., Miller, T.L., Mahone, E.M. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: A pilot study. Clin Neuropharmacol 2002, 25(6): 325-32.